Hospital Medicine Unplugged

Afleveringen

• Mixed Connective Tissue Disease in the Hospitalized Patient: Anti-U1 RNP, Overlap Syndromes, and the Lungs That Kill 03.06.2026 33min

  In this episode of Hospital Medicine Unplugged, we unpack mixed connective tissue disease—recognize the overlap syndrome hiding between lupus, scleroderma, and myositis, and aggressively monitor the pulmonary complications that drive morbidity and mortality. MCTD is defined by high-titer anti-U1 RNP antibodies plus overlapping connective tissue disease features. The hallmark clues:• Raynaud phenomenon• Swollen hands• Sclerodactyly• Inflammatory arthritis• Myositis• GERD and esophageal dysmotility Raynaud’s is often the earliest manifestation, and scleroderma-type findings help distinguish MCTD from lupus in anti-RNP–positive patients. The major threat is pulmonary disease:• Interstitial lung disease (ILD)• Pulmonary arterial hypertension (PAH) PAH remains the leading cause of death, making routine pulmonary surveillance essential:• Pulmonary function tests with DLCO• High-resolution CT when indicated• Echocardiography for PAH screening Treatment depends on organ involvement:• Steroids for inflammatory flares• Mycophenolate, methotrexate, or cyclophosphamide for ILD and systemic disease• Rituximab for refractory cases For MCTD-associated PAH:• Endothelin receptor antagonists• PDE-5 inhibitors• Prostacyclin pathway therapy• Immunosuppression may help more than in systemic sclerosis–associated PAH. Key pearl: many patients achieve remission or stable disease, but up to one-quarter eventually evolve into a more defined connective tissue disease—most commonly systemic sclerosis or lupus. We close with the system moves: don’t dismiss Raynaud’s plus swollen hands as “nonspecific,” screen aggressively for ILD and PAH, trend pulmonary function over time, and recognize that lung complications—not arthritis—determine long-term outcomes in MCTD. The antibody may define the diagnosis, but the lungs define the prognosis.
• Myelodysplastic Syndromes in the Hospitalized Patient: Clonal Cytopenias, Risk Stratification, and When to Transplant 01.06.2026 57min

  In this episode of Hospital Medicine Unplugged, we break down myelodysplastic syndromes—recognize the unexplained cytopenias, understand the modern molecular classification, and risk-stratify patients before progression to AML. The WHO 2022 classification shifted MDS from a purely morphologic disease to a genetically informed diagnosis. New entities include MDS with SF3B1 mutation, isolated del(5q), and biallelic TP53-mutated MDS, one of the highest-risk subtypes. Blast categories are now simplified into low blasts, increased blasts-1 (5–9%), and increased blasts-2 (10–19%). Diagnosis requires:• Persistent cytopenias• Dysplasia in >10% of a marrow lineage or defining cytogenetic abnormalities• Exclusion of alternative causes Bone marrow biopsy remains essential, and unexplained cytopenias with clonal mutations that don’t meet MDS criteria are now classified as CCUS. Risk stratification centers on the IPSS-R, incorporating:• Cytogenetics• Blast percentage• Hemoglobin• Platelets• Neutrophil count Lower-risk disease focuses on symptom control and transfusion reduction. Higher-risk disease focuses on delaying AML transformation and improving survival. For anemia in lower-risk MDS:• ESAs remain common first-line therapy• Luspatercept is especially effective in SF3B1-mutated or ring sideroblast disease and outperformed epoetin alfa in recent trials. For higher-risk disease:• Azacitidine is standard frontline therapy and improves overall survival• Decitabine is an alternative• Oral decitabine-cedazuridine allows outpatient treatment Key pearl: responses to hypomethylating agents are delayed—patients often need at least 4–6 cycles before declaring failure. The only curative therapy is allogeneic stem cell transplantation:• Consider for higher-risk disease and select lower-risk patients with severe cytopenias or poor-risk mutations• Reduced-intensity conditioning expanded transplant eligibility into older adults• TP53-mutated disease remains particularly challenging, even after transplant We close with the system moves: investigate unexplained macrocytic anemia and cytopenias early, integrate molecular testing into diagnosis and prognosis, avoid prematurely stopping hypomethylating therapy, and refer transplant-eligible patients before progression to AML. Not every pancytopenia is “just aging marrow”—sometimes it’s a clonal stem-cell disorder announcing itself before leukemia arrives.
• Cardiac Amyloidosis in the Hospitalized Patient: The HFpEF Diagnosis You’re Missing 29.05.2026 30min

  In this episode of Hospital Medicine Unplugged, we unpack cardiac amyloidosis—recognize the red flags hiding inside “routine HFpEF,” diagnose ATTR noninvasively, and start disease-modifying therapy before restrictive physiology becomes irreversible. ATTR cardiac amyloidosis is far more common than previously recognized, especially in older adults with HFpEF and increased LV wall thickness. Key clues include voltage-mass discordance—thick ventricles on echo with surprisingly low ECG voltage—and extracardiac findings like carpal tunnel syndrome, lumbar spinal stenosis, trigger finger, or biceps tendon rupture that may precede diagnosis by years. Echo pearls:• Increased wall thickness with preserved EF• Restrictive filling pattern• Biatrial enlargement• Classic “apical sparing” strain pattern The modern diagnostic breakthrough is nuclear imaging:• Grade 2–3 uptake on technetium-PYP scan + negative monoclonal protein testing = essentially diagnostic for ATTR-CM without biopsy. Never skip monoclonal protein screening:• Serum free light chains• Serum immunofixation• Urine immunofixation This distinction matters because AL amyloidosis is a hematologic emergency requiring plasma-cell–directed therapy. Treatment changed dramatically with tafamidis:• Reduces mortality• Lowers cardiovascular hospitalizations• Works best when started early Acoramidis joined the field in 2024 as another TTR stabilizer with similar benefits. Heart failure management is different here:• Loop diuretics are the backbone• ACE inhibitors, ARBs, and beta-blockers are often poorly tolerated• Avoid digoxin and non-dihydropyridine calcium channel blockers Key pearl: anticoagulate atrial fibrillation regardless of CHA₂DS₂-VASc score due to extreme thromboembolic risk. We close with the system moves: when HFpEF doesn’t quite fit—especially with unexplained LVH, neuropathy, orthopedic history, or voltage-mass discordance—think amyloid early, order monoclonal protein studies plus PYP scanning, and start disease-modifying therapy before fibrosis and restrictive failure dominate the trajectory. Not all HFpEF is hypertensive heart disease—sometimes the diagnosis is hiding in the carpal tunnel scar.
• Sarcoidosis in the Hospitalized Patient: Multisystem Granulomas and the Organs You Can’t Miss 27.05.2026 40min

  In this episode of Hospital Medicine Unplugged, we tackle sarcoidosis—recognize the classic presentations, screen aggressively for silent organ involvement, and treat the patients at highest risk for irreversible damage or sudden death. Diagnosis requires three things: compatible clinical presentation, non-caseating granulomas, and exclusion of alternative granulomatous disease like TB, fungal infection, or malignancy. Some syndromes are classic enough to skip biopsy, including Löfgren syndrome (bilateral hilar adenopathy, erythema nodosum, arthritis, fever) and lupus pernio. Most hospitalized patients, though, need tissue confirmation—typically via EBUS-guided transbronchial needle aspiration for intrathoracic lymphadenopathy. Once diagnosed, the mission shifts to multisystem screening:• Pulmonary: chest imaging + PFTs with DLCO• Cardiac: ECG for all patients; cardiac MRI or FDG PET for symptoms, arrhythmias, or conduction disease• Ophthalmologic: slit-lamp examination• Labs: CBC, creatinine, calcium, alkaline phosphatase, vitamin D metabolites when indicated Cardiac sarcoidosis is a major killer and can present with AV block, ventricular arrhythmias, syncope, or unexplained cardiomyopathy. Neurosarcoidosis can cause cranial neuropathies, meningitis, seizures, or spinal cord disease—both require aggressive recognition and treatment. Not all sarcoidosis needs therapy. Treat when there’s risk of organ damage, death, or severe symptoms:• Cardiac sarcoidosis• Neurosarcoidosis• Progressive pulmonary disease• Ocular disease• Symptomatic hypercalcemia Treatment backbone:• Prednisone 20–40 mg/day for most disease• Higher-dose steroids for cardiac/neuro involvement• IV methylprednisolone for life-threatening presentations Steroid-sparing therapy matters early:• Methotrexate is the preferred second-line agent• Azathioprine, mycophenolate, and leflunomide are alternatives• Infliximab or other biologics for refractory disease Cardiac sarcoidosis often needs more than immunosuppression:• ICDs for ventricular arrhythmia risk• Pacemakers for conduction disease• Catheter ablation for refractory VT Key inpatient pearls:• Monitor calcium and steroid toxicity• Use telemetry if cardiac involvement suspected• Watch for progressive hypoxemia or arrhythmias• Involve pulmonology, cardiology, ophthalmology, and neurology early We close with the system moves: build a standardized sarcoidosis screening pathway, default to ECG + pulmonary testing + ophthalmology evaluation at diagnosis, escalate rapidly to cardiac imaging when red flags appear, and initiate steroid-sparing therapy early for chronic disease. Granulomas are only the start—screen every organ, respect cardiac sarcoidosis, and treat before inflammation becomes permanent fibrosis.
• Autoimmune Encephalitis in a Hospitalized Patient: Diagnose Early, Treat Fast, Recover Long 25.05.2026 55min

  In this episode of Hospital Medicine Unplugged, we unpack autoimmune encephalitis—recognize the red flags early, treat aggressively before antibody results return, and support the long recovery arc that often extends years beyond discharge. We open with the bedside reality: autoimmune encephalitis is frequently missed because it masquerades as psychiatry, infection, toxic-metabolic disease, or unexplained delirium. The key clue is rapid progression over days to weeks with combinations of psychiatric symptoms, memory loss, seizures, dyskinesias, autonomic instability, speech dysfunction, or decreased consciousness. Diagnosis starts clinically—not with waiting for antibodies. The Graus 2016 framework emphasizes a tiered approach using history, exam, MRI, EEG, CSF, and syndrome recognition. For anti-NMDA receptor encephalitis, probable diagnosis requires rapid onset (<3 months) of at least four major symptom groups (psychiatric/cognitive dysfunction, speech dysfunction, seizures, movement disorder, decreased consciousness, autonomic dysfunction) plus abnormal EEG or CSF findings—or three symptom groups with a teratoma identified. Normal MRI does not exclude disease. Core diagnostic workup:• MRI brain with and without contrast• EEG (often diffuse slowing or extreme delta brush in anti-NMDAR disease)• Lumbar puncture with CSF cell count, protein, oligoclonal bands, infectious PCRs, autoimmune panels• Serum + CSF neuronal antibody testing• Broad infectious exclusion—especially HSV encephalitis• Tumor screening (ovarian teratoma, thymoma, small-cell lung cancer, etc.) The critical management principle: do not delay immunotherapy waiting for antibodies. Seronegative autoimmune encephalitis exists, testing sensitivity is imperfect, and treatment delay worsens outcomes. First-line therapy builds the immunotherapy backbone:• High-dose corticosteroids• IVIG• Plasma exchange (PLEX) Evidence increasingly favors combination therapy over isolated treatment. Meta-analysis data from >1,500 patients showed therapeutic apheresis alone or combination regimens (steroids + IVIG or all three modalities) had the best odds of favorable recovery. Failure to initiate immunotherapy within 30 days was associated with markedly worse outcomes. If first-line treatment stalls:• Rituximab becomes the preferred second-line agent• Cyclophosphamide remains an option in refractory disease• Escalation should happen early in severe or persistent cases rather than waiting months Rituximab deserves special attention—it not only improves refractory disease but also substantially lowers relapse risk, with studies demonstrating nearly a six-fold reduction in recurrence odds. ICU pearls you don’t want to miss:• Autonomic instability can become life-threatening• Refractory seizures and status epilepticus are common• Dyskinesias may require deep sedation• Ventilator dependence is frequent in severe anti-NMDAR disease• Always continue aggressive rehabilitation planning early Tumor search is not optional:• Ovarian teratoma in young women with anti-NMDAR encephalitis• Thymoma in LGI1/CASPR2 syndromes• Small-cell lung cancer in classic paraneoplastic syndromes When present, tumor removal is treatment and significantly affects relapse risk and neurologic recovery. Recovery is where expectations need recalibration. Improvement is often slow, nonlinear, and incomplete despite “good” functional scores. About 75–81% of anti-NMDAR patients eventually achieve substantial recovery, but progress may continue for 24–36 months. The largest gains occur in the first 6 months, yet persistent deficits in memory, language, fatigue, emotional health, and social functioning are extremely common. One of the most important recent observations: autoimmune encephalitis patients continue improving well beyond the timeline expected for infectious encephalitis. Critically ill autoimmune cases may show functional gains throughout the entire first year, reinforcing the importance of prol
• Acute Interstitial Nephritis in the Hospitalized Patient: Drug-Induced AKI and Modern Diagnosis 20.04.2026 48min

  In this episode of Hospital Medicine Unplugged, we unpack acute interstitial nephritis (AIN)—a frequently overlooked cause of acute kidney injury (AKI) driven largely by medications, immune reactions, and systemic diseases. We start with epidemiology clinicians should recognize. AIN accounts for roughly 15–27% of kidney biopsies performed for AKI and about 2.8% of all kidney biopsies overall. Among biopsies done specifically for acute renal failure, AIN represents ~13.5% of cases. Drug-induced AIN dominates the landscape, responsible for 70–90% of biopsy-proven cases, and its incidence appears to be rising—particularly in older adults, where polypharmacy and underutilization of kidney biopsy can obscure the diagnosis. Next we break down the most common causes.• Antibiotics are the leading class, responsible for ~49% of drug-induced AIN, especially penicillins, cephalosporins, rifampin, and fluoroquinolones.• Proton pump inhibitors account for ~14%, with omeprazole the single most common culprit drug.• NSAIDs (~11%) are another major contributor.Other causes include 5-aminosalicylates, diuretics, allopurinol, anticonvulsants, and chemotherapeutic agents. Emerging causes include immune checkpoint inhibitors, reflecting the expanding use of immunotherapy in oncology. We then explore the immunologic pathophysiology. AIN is primarily driven by T-cell–mediated hypersensitivity reactions (Type IV) targeting tubular antigens or drug-related antigens processed by tubular epithelial cells. However, IgE-mediated mast cell activation (Type I hypersensitivity) may also contribute in some cases. The resulting interstitial inflammation and edema can rapidly progress to fibrosis, making early recognition and treatment critical for renal recovery. Histologically, AIN is characterized by interstitial inflammatory infiltrates composed mainly of lymphocytes, macrophages, plasma cells, and sometimes eosinophils, along with tubulitis, interstitial edema, and tubular injury. Glomeruli are typically normal, while interstitial fibrosis and tubular atrophy signal chronicity and worse prognosis. Variants include granulomatous AIN and rare entities like IgM-positive plasma cell tubulointerstitial nephritis. Clinically, the classic triad of fever, rash, and eosinophilia is now uncommon—present in fewer than 10–15% of patients. Instead, most patients present with nonspecific symptoms such as malaise, nausea, or asymptomatic AKI. Non-oliguric AKI is typical, often accompanied by mild proteinuria and tubular dysfunction. Diagnosis relies on clinical suspicion, medication review, and supportive laboratory findings. Urinalysis may show sterile pyuria and white blood cell casts, which are more specific for AIN. Eosinophiluria, historically emphasized, is neither sensitive nor specific. Ultimately, kidney biopsy remains the gold standard when the diagnosis is uncertain. We also review emerging biomarkers that may transform diagnosis. Urinary CXCL9, an interferon-γ–induced chemokine involved in lymphocyte recruitment, has shown excellent diagnostic performance with AUC values up to ~0.94 for AIN detection. Additional candidate biomarkers include urinary TNF-α, IL-9, kidney injury molecule-1 (KIM-1), and soluble C5b-9, reflecting tubular injury and immune activation. Management begins with immediate withdrawal of the offending drug. If kidney function does not improve within 5–7 days, corticosteroid therapy is often initiated, typically prednisone ~40–60 mg daily (~0.8 mg/kg). Evidence suggests that early steroid therapy—within the first 1–2 weeks—improves renal recovery, while prolonged treatment beyond several weeks offers little additional benefit. Finally, we discuss prognosis. About 76% of patients achieve some degree of kidney recovery within six months, with complete recovery in roughly half of steroid-treated cases. However, chronic kidney disease remains common, and long-term studies suggest up to 39% of patients may eventually develop end-sta
• Celiac Disease in the Hospitalized Patient: Diagnosis, Complications, and the Future Beyond Gluten-Free Diets 17.04.2026 1u 3min

  In this episode of Hospital Medicine Unplugged, we break down celiac disease—from epidemiology and modern diagnostic strategies to life-threatening complications and emerging therapies beyond the gluten-free diet. We start with epidemiology clinicians should know. The global prevalence of celiac disease is ~1.4% based on serology and ~0.7% with biopsy confirmation. Incidence rates are ~17 per 100,000 person-years in women and ~8 per 100,000 in men, with a female-to-male ratio of ~1.8. Importantly, about 70% of cases remain undiagnosed, the so-called “celiac iceberg.” Over recent decades, incidence has increased substantially, rising from <2 per 100,000 annually in the 1980s to >20 per 100,000 in many regions today. Next we unpack genetic susceptibility and immune pathogenesis. Nearly all patients carry HLA-DQ2 or HLA-DQ8, but these genes alone are insufficient—~40% of the population carries them, yet only 1–3% develop disease, highlighting the role of environmental triggers and additional genetic factors. Gluten exposure leads to immune activation against deamidated gliadin peptides, resulting in small-intestinal inflammation, villous atrophy, and malabsorption. We then highlight how the clinical presentation has shifted. The classic picture of malabsorption with diarrhea and weight loss is now less common in adults. Instead, non-classical presentations predominate, including iron-deficiency anemia, osteoporosis, abnormal liver enzymes, infertility, and nonspecific GI symptoms. Diarrhea still occurs in ~40–50% of patients, but many adults present with extraintestinal manifestations or even asymptomatic disease. We also review celiac crisis, a rare but life-threatening presentation requiring hospitalization. Patients develop severe diarrhea, dehydration, electrolyte disturbances, metabolic acidosis, and profound malnutrition. Management requires intravenous fluids, electrolyte replacement, aggressive nutritional support, and sometimes corticosteroids, alongside initiation of a strict gluten-free diet, which leads to improvement in the vast majority of patients. Diagnosis begins with serologic testing. IgA tissue transglutaminase (tTG-IgA) is the preferred initial screening test, with ~93–95% sensitivity and ~95–98% specificity, and total IgA should be measured simultaneously to detect IgA deficiency. Endomysial antibody testing has near-100% specificity and can confirm the diagnosis. In adults, upper endoscopy with small-bowel biopsy remains the diagnostic standard, demonstrating intraepithelial lymphocytosis, crypt hyperplasia, and villous atrophy. We then discuss major complications clinicians must recognize. These include osteoporosis, infertility, neurologic complications, hyposplenism, and small-bowel adenocarcinoma. One of the most serious is enteropathy-associated T-cell lymphoma (EATL)—a rare but aggressive malignancy with very poor survival, often arising from type 2 refractory celiac disease. Refractory celiac disease (RCD) occurs when symptoms and villous atrophy persist despite ≥12 months of strict gluten-free diet.• Type 1 RCD behaves similarly to active celiac disease and responds to immunosuppressive therapy with excellent survival.• Type 2 RCD represents a pre-lymphoma state with clonal abnormal lymphocytes, and 30–50% progress to EATL within five years. Management still centers on the gluten-free diet, which leads to symptomatic improvement in ~70% of patients within two weeks, though histologic healing can take months and may remain incomplete in many adults. Finally, we explore the future of therapy. While diet remains the cornerstone, multiple pharmacologic strategies are in development, including gluten-degrading enzymes, intestinal barrier modulators like larazotide, transglutaminase inhibitors, immune-modulating therapies targeting IL-15, microbiome-based therapies, and even gene-edited wheat with reduced immunogenic gluten. The takeaway: celiac disease is common, frequently underdiagnos
• Polypharmacy & Deprescribing in the Hospitalized Patient: Safer Medication Use in Older Adults 15.04.2026 44min

  In this episode of Hospital Medicine Unplugged, we tackle polypharmacy and deprescribing—how to recognize problematic medication overload, quantify its harms, and apply structured, patient-centered strategies to safely reduce medication burden. We begin with definitions that shape clinical practice. Polypharmacy is most commonly defined as the use of ≥5 medications, though definitions vary. Importantly, not all polypharmacy is harmful. “Appropriate polypharmacy” occurs when medications are evidence-based and optimized, while “problematic polypharmacy” arises when medications lack clear benefit or when harms outweigh benefits. Deprescribing is the systematic process of identifying and discontinuing medications whose risks exceed benefits, aligned with a patient’s goals, function, life expectancy, and preferences. Next we review how common this problem is. Polypharmacy affects 30–40% of community-dwelling older adults, 40–50% of hospitalized older adults, and up to 90% of nursing home residents. Roughly 20–50% of older adults take at least one potentially inappropriate medication (PIM). Risk rises with multimorbidity, female sex, lower socioeconomic status, and each additional chronic disease increases the odds of polypharmacy by nearly 90%. We then quantify the clinical consequences.• Adverse drug events occur in 20–30% of hospitalized older adults, and each additional medication increases adverse reaction risk by ~10%.• Polypharmacy is associated with higher mortality (HR ~1.2–1.7) and increased hospital admissions and readmissions.• It also increases fall risk (OR ~1.6) and contributes to hip fractures, frailty, cognitive impairment, and functional decline. A key driver is the prescribing cascade, where a drug causes side effects that are treated with additional medications. Classic examples include:• NSAIDs → hypertension → antihypertensives• Cholinesterase inhibitors → urinary incontinence → anticholinergics• Calcium channel blockers → edema → diuretics• Antipsychotics → parkinsonism → antiparkinsonian drugs To identify problematic medications, we review major screening tools.• 2023 AGS Beers Criteria highlights medications to avoid or use cautiously in older adults, including guidance on benzodiazepines, antipsychotics in dementia, and aspirin for primary prevention in adults ≥70.• STOPP/START version 3 includes 94 criteria for inappropriate prescriptions and 34 for underprescribing.• Additional tools include the Medication Appropriateness Index, FORTA classification, Anticholinergic Cognitive Burden scale, and Drug Burden Index. We then walk through a practical deprescribing framework. A common 5-step protocol includes: List all medications and indications Assess overall risk of drug-related harm Identify drugs eligible for discontinuation Prioritize those with highest harm and lowest benefit Implement tapering and monitor for withdrawal or recurrence Certain medications require careful tapering to prevent withdrawal syndromes, including benzodiazepines, beta-blockers, antidepressants, corticosteroids, opioids, antiepileptics, clonidine, baclofen, and proton pump inhibitors. We highlight high-yield deprescribing targets.• Proton pump inhibitors: up to 70% lack appropriate indication; associated with C. difficile infection, pneumonia, CKD, and fractures.• Benzodiazepines: linked to falls, delirium, and cognitive impairment, with tapering success rates 27–80%.• Antipsychotics: frequently used for dementia behaviors but carry 1.6–1.7× increased mortality risk.• Anticholinergic medications: high burden strongly linked to cognitive decline and mortality.• Sliding-scale insulin: increases hypoglycemia without improving glycemic control. We also discuss patient and system barriers. Interestingly, 92% of older adults say they would stop at least one medication if their doctor recommended it, though many fear symptom recurrence or believe medications are necessary. Finally, we examine solutions that work. P
• Primary Hyperparathyroidism in the Hospitalized Patient: Diagnosis, Imaging, and When to Operate 13.04.2026 39min

  In this episode of Hospital Medicine Unplugged, we break down primary hyperparathyroidism (PHPT)—from epidemiology and pathophysiology to modern imaging, surgical indications, and evolving medical therapies. We start with who gets PHPT and how often it occurs. The condition affects ~0.8–0.9% of the general population, with an incidence of 4–6 cases per 10,000 person-years. It is 2.5 times more common in women, and incidence rises sharply with age, reaching ~12 cases per 10,000 person-years in people aged 70–79. There are also racial disparities, with higher incidence reported in Black populations. Next we unpack the causes of PHPT. About 80% of cases result from a single parathyroid adenoma, 10–11% from multiple adenomas, <10% from four-gland hyperplasia, and <1% from parathyroid carcinoma. Some cases occur in genetic syndromes such as MEN1, MEN2A, MEN4, and hyperparathyroidism–jaw tumor syndrome. Clinically, up to 80% of patients in resource-rich settings are now asymptomatic, discovered incidentally through routine lab testing. When symptoms occur, they reflect hypercalcemia and PTH excess, including kidney stones, osteoporosis, gastrointestinal symptoms, and neuromuscular complaints. Many patients also report fatigue, depression, or cognitive symptoms, though the direct causal relationship remains debated. We then cover complications that drive treatment decisions. PHPT can lead to osteoporosis, fragility fractures, nephrolithiasis, and reduced kidney function. There is also growing evidence linking PHPT with hypertension, left ventricular hypertrophy, and increased cardiovascular risk, though cardiovascular benefit from surgery remains uncertain. Diagnosis starts with biochemical confirmation—elevated calcium with inappropriately elevated PTH. Imaging is not for diagnosis but for surgical planning. The usual first-line localization strategy combines neck ultrasound with dual-tracer sestamibi scanning, while second-line imaging options such as 4D-CT or 18F-fluorocholine PET/CT offer extremely high sensitivity—up to ~94–99%. Management centers on parathyroidectomy, which is the definitive treatment. Current guidelines recommend surgery for patients with:• Serum calcium >1 mg/dL above normal• Age <50 years• Osteoporosis (T-score ≤ −2.5) or vertebral fracture• Kidney disease (eGFR <60)• Hypercalciuria (>250 mg/day in women, >300 mg/day in men)• Kidney stones or nephrocalcinosis• Symptomatic disease For patients who are not surgical candidates, several medications help control complications:• Cinacalcet lowers serum calcium and PTH but does not improve bone density• Bisphosphonates (like alendronate) improve bone density but do not lower calcium• Denosumab and combination therapy with cinacalcet may help address both hypercalcemia and bone loss We also explore normocalcemic primary hyperparathyroidism, an increasingly recognized condition defined by elevated PTH with normal calcium after excluding secondary causes. It may represent an early or milder form of PHPT, often with more multiglandular disease and slightly lower surgical cure rates. Finally, we highlight critical diagnostic pitfalls and emerging research. Distinguishing PHPT from familial hypocalciuric hypercalcemia (FHH) is essential—FHH shows lifelong mild hypercalcemia and a calcium-to-creatinine clearance ratio <0.01 and does not require surgery. Meanwhile, advanced imaging, genetic testing in younger patients, and combination pharmacotherapy are shaping the future of PHPT care. The bottom line: primary hyperparathyroidism is common, increasingly detected incidentally, and highly treatable—especially when clinicians recognize surgical indications, use modern imaging strategies, and tailor therapy to complications and patient risk.
• ANCA Vasculitis: From Pathophysiology to Precision Treatment in the Hospitalized Patient 10.04.2026 32min

  In this episode of Hospital Medicine Unplugged, we break down ANCA-associated vasculitis (AAV)—granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA)—focusing on modern epidemiology, complement-driven pathophysiology, ANCA serotypes, and the rapidly evolving treatment landscape. We start with epidemiology clinicians should recognize. The global incidence of AAV is ~17 per million person-years, with a prevalence near 198 per million. In the United States, incidence is roughly 3.3 per 100,000, with a prevalence of ~42 per 100,000. Subtype incidence varies: GPA (~9–15/million), MPA (~6/million), and EGPA (~2/million). The mean age at diagnosis is about 61, and rates have increased over the past decades due to greater recognition and widespread ANCA testing. Next we unpack the pathophysiology that changed therapy. Complement activation—particularly the alternative pathway—plays a central role. C5a drives neutrophil activation and recruitment, creating an inflammatory amplification loop. Low C3 levels correlate with more aggressive disease and worse renal outcomes. This mechanistic insight led to avacopan, an oral C5a receptor antagonist that provides a glucocorticoid-sparing approach to treatment. We then highlight the importance of ANCA serotype classification. Patients are increasingly categorized by PR3-ANCA vs MPO-ANCA, not just clinical phenotype.• PR3-ANCA disease is more often GPA, with ENT involvement, pulmonary nodules, and higher relapse risk.• MPO-ANCA disease more often presents as MPA, with renal-limited disease, interstitial lung disease, and higher mortality. We also review EGPA as a distinct entity. Only ~40% of patients are ANCA-positive. Two clinical subsets exist:• ANCA-positive EGPA → vasculitic manifestations such as glomerulonephritis and neuropathy• ANCA-negative EGPA → eosinophilic disease with pulmonary infiltrates and cardiomyopathyAsthma is a defining feature, and cardiac involvement is a major driver of mortality. Diagnosis relies on modern ANCA testing and organ evaluation. PR3- and MPO-specific immunoassays are now the preferred screening tests, with ~90–95% sensitivity for active GPA/MPA and >95% specificity. Renal disease occurs in 70–80% of GPA/MPA, typically as pauci-immune necrotizing crescentic glomerulonephritis, while pulmonary disease ranges from nodules and cavitation (PR3) to interstitial lung disease (MPO) and diffuse alveolar hemorrhage. Management has evolved dramatically. First-line induction therapy combines glucocorticoids with rituximab or cyclophosphamide, with rituximab preferred for most patients—especially PR3-ANCA or relapsing disease. Reduced-dose steroid regimens are now recommended after trials like PEXIVAS, which showed lower infection risk without worse renal outcomes. We also cover key modern therapies.• Avacopan, a C5a receptor antagonist, improves sustained remission and kidney recovery while reducing steroid exposure.• Plasma exchange remains controversial after the PEXIVAS trial, but may still be considered in severe kidney failure, dialysis-dependent disease, or diffuse alveolar hemorrhage. For maintenance therapy, rituximab is now the preferred agent, outperforming azathioprine in major trials such as MAINRITSAN and RITAZAREM. Maintenance typically continues 2–4 years, especially in PR3-ANCA patients with high relapse risk. We finish with EGPA-specific treatment advances. IL-5 pathway inhibitors have transformed care, including mepolizumab and the newer benralizumab, which improve remission rates and allow significant glucocorticoid reduction. The bottom line: AAV management has shifted toward precision medicine—ANCA serotype classification, complement-targeted therapy, steroid-sparing strategies, and biologic maintenance treatments—dramatically improving survival and long-term outcomes.
• Clinical Management and Metabolism of Fat-Soluble Vitamins in the Hospitalized Patient 08.04.2026 29min

  In this episode of Hospital Medicine Unplugged, we sprint through fat-soluble vitamins—A, D, E, and K—focusing on how they’re absorbed, why deficiencies happen, and the clinical syndromes hospitalists must recognize early. From intestinal transporters to neurologic deficits and neonatal bleeding, we connect physiology to bedside decision-making. We start with absorption mechanics, which are more complex than simple passive diffusion. Modern research shows specific intestinal transporters—SR-BI, CD36, NPC1L1, and ABCA1—facilitate uptake of vitamins D, E, and K. Interestingly, vitamin A appears to lack a dedicated membrane transporter for dietary absorption. Absorption is also competitive: vitamins D, E, and K compete with one another, while vitamin A can suppress absorption of other fat-soluble vitamins without being affected itself. This interaction becomes clinically relevant in patients taking high-dose supplements. Next we tackle vitamin A—vision, epithelial integrity, and immune defense. Deficiency follows a classic progression:• Night blindness (earliest symptom)• Xerophthalmia• Bitot spots• Irreversible corneal damage and blindness Vitamin A also regulates epithelial differentiation and T-cell immune function, so deficiency increases susceptibility to infection. Even in high-income settings, restrictive diets or selective eating can lead to severe deficiency and permanent ocular injury. Toxicity is equally important. Chronic hypervitaminosis A causes:• Elevated intracranial pressure (headache, vomiting, papilledema, bulging fontanelle in infants)• Hepatotoxicity• Bone abnormalities from vitamin D receptor antagonism• Teratogenic effects Sustained doses around 50,000 IU daily for >18 months can produce chronic toxicity. We then shift to vitamin D—arguably the most clinically debated fat-soluble vitamin. Vitamin D metabolism follows a three-step pathway: UVB exposure converts 7-dehydrocholesterol in skin to vitamin D3 Hepatic conversion to 25-hydroxyvitamin D (calcidiol) Renal activation to calcitriol (1,25-dihydroxyvitamin D) This active hormone regulates calcium and phosphate homeostasis through tight feedback with parathyroid hormone. Deficiency is widespread—over one billion people globally. Classic consequences include rickets in children and osteomalacia or osteoporosis in adults, but deficiency also contributes to proximal muscle weakness, increasing fall and fracture risk. Vitamin D receptors are expressed throughout the body, and observational data link deficiency with cardiovascular disease, autoimmune disease, diabetes, multiple sclerosis, and cancer, although randomized trials show mixed results for extraskeletal benefits. A key clinical debate remains optimal levels. Many experts advocate serum 25-hydroxyvitamin D concentrations above 40–50 ng/mL, often requiring supplementation beyond traditional recommendations. Next up: vitamin E—the neurologic protector. Deficiency primarily manifests with neurologic disease, including:• Peripheral neuropathy• Cerebellar and sensory ataxia• Posterior column dysfunction• Hyporeflexia• Oculomotor abnormalities such as impaired upward gaze Severe cases can progress to blindness and dementia. In cholestatic patients, interpretation requires nuance. Vitamin E levels may appear falsely normal due to hyperlipidemia, so clinicians should measure the vitamin E–to–total lipid ratio instead. Another diagnostic clue is red blood cell acanthocytosis on blood smear. Toxicity is uncommon but high-dose vitamin E increases bleeding risk, particularly in patients taking anticoagulants. We close with vitamin K—the coagulation vitamin with expanding roles in vascular biology. Vitamin K enables γ-carboxylation of clotting factors II, VII, IX, and X and anticoagulant proteins C and S. Deficiency produces functional clotting factor impairment and bleeding once levels fall below ~30 U/dL. In neonates, vitamin K deficiency bleeding (VKDB) occurs in three forms:• Early (<2
• Thalassemias: Genetics, Pathophysiology, and Clinical Manifestations in the Hospitalized Patient 06.04.2026 35min

  In this episode of Hospital Medicine Unplugged, we sprint through thalassemia—an inherited hemoglobinopathy defined by reduced or absent globin chain production, ineffective erythropoiesis, and chronic anemia. We break down the genetics, pathophysiology, clinical spectrum, and why this disorder remains the most common monogenic disease worldwide. We start with the big picture. About 5% of the global population carries an α-thalassemia allele and 1.5% carries a β-thalassemia allele, with roughly 1.3 million people living with disease and ~40,000 affected infants born annually. The condition clusters across malaria-endemic regions—from sub-Saharan Africa and the Mediterranean to the Middle East, South Asia, and Southeast Asia—because the carrier state provides partial protection against malaria. Migration has increasingly brought thalassemia to North America and Europe, expanding its global clinical impact. Next, we revisit normal hemoglobin physiology. Adult hemoglobin (HbA) is α₂β₂, with smaller fractions of HbA₂ (α₂δ₂) and HbF (α₂γ₂). During infancy, the body transitions from fetal hemoglobin to adult hemoglobin as γ-globin declines and β-globin production increases, regulated by transcription factors such as BCL11A and KLF1. Balanced α- and β-chain production is essential—when the balance breaks, unpaired globin chains accumulate, precipitate, and damage developing red cells, driving ineffective erythropoiesis. We then dive into the genetic architecture.α-globin genes (HBA1, HBA2) sit on chromosome 16 with four total copies, while the β-globin gene (HBB) lies on chromosome 11 with two total copies. • α-thalassemia is usually caused by gene deletions affecting HBA1 or HBA2.• β-thalassemia typically results from point mutations affecting transcription, RNA splicing, or translation. Mutations are classified as:• β⁰ mutations: no β-globin production• β⁺ mutations: reduced β-globin synthesis Severity depends on genotype, but genetic modifiers matter—coinherited α-thalassemia, increased HbF production, or α-globin gene duplications can significantly alter disease expression. Next, we map the clinical classification. Alpha thalassemia spectrum:• Silent carrier: one gene affected, usually asymptomatic• α-thalassemia trait: two genes affected, mild microcytic anemia• Hemoglobin H disease: three genes affected → moderate-severe hemolytic anemia with β₄ tetramers• Hb Bart’s hydrops fetalis: four genes deleted → incompatible with life Beta thalassemia spectrum:• β-thalassemia trait: mild microcytic anemia with elevated HbA₂ (>3.5%)• β-thalassemia intermedia: moderate anemia with variable transfusion needs• β-thalassemia major (Cooley anemia): severe disease presenting in infancy requiring lifelong transfusions Compound disorders add complexity, including HbE-β thalassemia and sickle-β thalassemia, where severity depends on the interacting mutations. Then we unpack the pathophysiology driving complications. Excess unpaired globin chains cause oxidative damage and premature death of erythroid precursors, leading to:• Ineffective erythropoiesis with massive marrow expansion• Hemolysis from fragile red cells• Extramedullary hematopoiesis in liver and spleen Chronic erythropoietin stimulation leads to skeletal deformities—frontal bossing, maxillary hypertrophy, and long-bone abnormalities. Iron overload develops through two major pathways:• Transfusion iron loading (each unit adds ~200–250 mg of iron)• Increased intestinal absorption from suppressed hepcidin due to ineffective erythropoiesis The downstream damage is systemic: cardiomyopathy, arrhythmias, liver fibrosis and cirrhosis, endocrine failure (growth delay, diabetes, hypothyroidism, hypoparathyroidism), osteoporosis, and thrombosis risk. We close with the clinical spectrum. • Trait: usually asymptomatic with incidental microcytosis• Intermedia: moderate anemia (Hb ~7–10 g/dL), skeletal changes, gallstones, pulmonary hypertension, extramedullary masses• Major: early in
• Clinical Guide to Axial Spondyloarthritis and Ankylosing Spondylitis 03.04.2026 21min

  In this episode of Hospital Medicine Unplugged, we sprint through ankylosing spondylitis and axial spondyloarthritis—recognize inflammatory back pain early, understand the disease spectrum from non-radiographic to radiographic disease, and treat aggressively to prevent structural damage and disability. We begin with the modern concept of axial spondyloarthritis (axSpA), which represents a disease spectrum rather than a single condition. At one end is non-radiographic axial spondyloarthritis (nr-axSpA)—patients with typical symptoms but without definitive radiographic sacroiliitis. At the other end is radiographic axial spondyloarthritis (r-axSpA), historically known as ankylosing spondylitis, where structural changes in the sacroiliac joints are visible on X-ray. Globally, axial spondyloarthritis affects roughly 0.3% to 1.4% of the population, with about 1% prevalence in the United States. Disease onset typically occurs early in life—more than 80% of patients develop symptoms before age 30. Radiographic disease is more common in men, while non-radiographic disease occurs equally in men and women. A major challenge in this condition is diagnostic delay, which averages nearly seven years from symptom onset. This delay contributes to progressive inflammation, structural damage, and functional impairment before effective therapy is started. The pathogenesis of axial spondyloarthritis involves a combination of genetic susceptibility, immune dysregulation, and environmental triggers. The strongest genetic risk factor is HLA-B27, present in 80–90% of patients with ankylosing spondylitis. Several mechanisms have been proposed to explain how HLA-B27 contributes to disease: • Presentation of arthritogenic peptides to CD8+ T cells• Formation of HLA-B27 dimers, which activate innate immune receptors• Misfolding of HLA-B27 proteins, triggering an unfolded protein response and increased cytokine signaling At the center of the inflammatory cascade lies the IL-23 / IL-17 axis, which drives activation of Th17 cells and production of pro-inflammatory cytokines including IL-17 and TNF-α. Mechanical stress at the entheses—the sites where ligaments and tendons attach to bone—triggers inflammation, making enthesitis the hallmark pathological process. Chronic inflammation eventually stimulates pathologic new bone formation, producing syndesmophytes and spinal ankylosis. Clinically, the hallmark symptom is inflammatory back pain, present in more than 80% of patients. Key features include: • Onset before age 45 years• Gradual onset• Morning stiffness lasting more than 30 minutes• Improvement with exercise• No improvement with rest Extra-articular manifestations are common and often provide diagnostic clues. The most frequent is acute anterior uveitis, occurring in 25–30% of patients. Episodes typically present with sudden eye pain, redness, photophobia, and blurred vision. Other associated conditions include: • Inflammatory bowel disease (5–10%)• Psoriasis (about 10%)• Cardiovascular involvement, including aortic regurgitation and conduction abnormalities• Pulmonary restriction due to chest wall rigidity Because early disease may not show radiographic damage, classification relies on modern criteria. The Modified New York Criteria require definite radiographic sacroiliitis and therefore identify only advanced disease. In contrast, the ASAS classification criteria for axial spondyloarthritis allow earlier diagnosis. These criteria apply to patients with chronic back pain lasting ≥3 months with onset before age 45 and include two diagnostic pathways: • Imaging arm: sacroiliitis on MRI or radiograph plus ≥1 SpA feature• Clinical arm: HLA-B27 positivity plus ≥2 SpA features These criteria have approximately 83% sensitivity and 84% specificity, enabling detection of earlier disease stages. Monitoring disease activity is critical to guide treatment decisions. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is the preferred measure beca
• Prosthetic Heart Valve Selection and Clinical Management Guide for the Hospitalist 01.04.2026 34min

  In this episode of Hospital Medicine Unplugged, we sprint through prosthetic heart valves—how to choose between mechanical and bioprosthetic valves, manage anticoagulation safely, recognize complications, and navigate the expanding role of transcatheter valve replacement. We begin with the two major categories of prosthetic valves: mechanical valves and bioprosthetic (tissue) valves. Mechanical valves are constructed from durable materials such as pyrolytic carbon and are designed to last decades, but their thrombogenic surface requires lifelong anticoagulation with a vitamin K antagonist. Anticoagulation targets depend on valve position and risk factors.• Mechanical aortic valve: target INR 2.5• Mechanical mitral valve or high-risk aortic valve: target INR 3.0 In most patients, low-dose aspirin (75–100 mg daily) is added to vitamin K antagonist therapy to further reduce thromboembolic risk. Bioprosthetic valves, in contrast, are made from porcine valves or bovine pericardium. These valves are less thrombogenic, which allows for short-term anticoagulation (typically 3–6 months) after implantation followed by lifelong antiplatelet therapy with aspirin. The trade-off is durability—structural valve degeneration (SVD) eventually occurs due to calcification, fibrosis, or leaflet tearing. Choosing between valve types requires balancing durability versus anticoagulation risk. Mechanical valves generally offer better long-term durability, while bioprosthetic valves avoid lifelong anticoagulation but may require future reoperation. Age is one of the most important factors in valve selection. Evidence from large observational studies demonstrates that mechanical valves provide survival advantages in younger patients, particularly:• Aortic valve replacement: survival benefit up to about age 55• Mitral valve replacement: survival benefit up to about age 70 Current ACC/AHA guidelines generally recommend:• Mechanical valves: younger patients (<50 years for aortic position, <65 years for mitral)• Bioprosthetic valves: older patients or those with contraindications to long-term anticoagulation The treatment landscape has changed dramatically with the development of transcatheter aortic valve replacement (TAVR). Initially reserved for patients with prohibitive surgical risk, TAVR is now widely used across risk groups. Landmark trials such as PARTNER 3 demonstrated that in low-risk patients with severe aortic stenosis, TAVR produced outcomes comparable to surgical valve replacement at five years. TAVR offers advantages including lower rates of atrial fibrillation and bleeding, though it carries higher risks of paravalvular regurgitation and pacemaker implantation. Guidelines now recommend:• TAVR as a Class I option for patients who are inoperable or high surgical risk• Either TAVR or surgical replacement for patients aged 65–80 years, depending on anatomy and patient factors Anticoagulation management remains one of the most critical aspects of prosthetic valve care. Direct oral anticoagulants (DOACs are contraindicated in mechanical valves). The RE-ALIGN trial showed increased thromboembolic and bleeding complications with dabigatran compared with warfarin, leading to early termination of the study. More recently, the PROACT Xa trial evaluating apixaban in patients with On-X mechanical valves also demonstrated excess thromboembolic events. For bioprosthetic valves, however, DOACs may be used in patients who develop atrial fibrillation, although long-term data remain limited. Despite technological advances, prosthetic valves carry important complications. One of the most serious is prosthetic valve endocarditis (PVE), which is associated with high mortality. Management requires prolonged intravenous antibiotics, typically for at least six weeks, and surgery may be required for heart failure, uncontrolled infection, or large vegetations. Another major complication is prosthetic valve thrombosis, particularly with mechanical val
• Asbestosis: Pathogenesis, Clinical Diagnosis, and Management Strategies in the Hospitalized Patient 30.03.2026 29min

  In this episode of Hospital Medicine Unplugged, we sprint through asbestosis—understand how inhaled fibers trigger progressive pulmonary fibrosis, recognize key radiographic features, and manage patients with attention to malignancy risk and progressive fibrotic disease. We start with pathophysiology, where the story begins decades before symptoms appear. After inhalation, asbestos fibers deposit in the distal airways and alveoli. Alveolar macrophages attempt to engulf these fibers, but many fibers are too long to be fully internalized—triggering “frustrated phagocytosis.” This leads to persistent macrophage activation and release of inflammatory mediators including TNF-α, IL-1, and TGF-β. At the same time, reactive oxygen species form both from macrophage activation and from iron on the fiber surface, amplifying oxidative injury. A key early event is alveolar epithelial cell apoptosis, driven by mitochondrial injury, p53-mediated pathways, and endoplasmic reticulum stress. Loss of epithelial integrity and chronic inflammation stimulate fibroblast activation and collagen deposition, ultimately producing the progressive interstitial fibrosis that defines asbestosis. Not all asbestos fibers carry the same risk. Amphibole fibers—particularly crocidolite and amosite—are far more fibrogenic and carcinogenic than chrysotile fibers. Their needle-like shape, durability, and resistance to biological clearance allow them to persist in lung tissue for decades. Fiber dimensions matter: long fibers (>10–20 μm) and extremely thin fibers (<0.25 μm) pose the highest disease risk because they reach distal lung regions and resist macrophage clearance. One of the defining features of asbestos disease is extraordinary latency. Clinical asbestosis usually develops 20–40 years after the first exposure, with peak disease occurrence around 40–45 years after exposure begins. Lung cancer tends to occur earlier, typically 30–35 years after exposure. Disease progression varies—some patients remain stable while others develop progressive fibrotic lung disease with significant annual declines in FVC, particularly those with fibrotic patterns on HRCT. Diagnosis relies on a combination of exposure history, latency, imaging, and pulmonary function testing. According to consensus guidelines, the diagnosis requires: • Documented asbestos exposure• Appropriate latency interval• Radiographic evidence of interstitial fibrosis• Restrictive lung disease with reduced DLCO While chest X-ray can detect classic small irregular opacities, high-resolution CT is far more sensitive. Key HRCT findings include: • Subpleural curvilinear lines (one of the most specific findings)• Intralobular and interlobular septal thickening• Parenchymal bands• Honeycombing in advanced disease Importantly, most patients with asbestosis also show benign pleural abnormalities, such as pleural plaques or diaphragmatic pleural thickening, which strongly support asbestos exposure. Unfortunately, no disease-modifying therapies are currently approved specifically for asbestosis. Management traditionally focuses on supportive care, including: • Smoking cessation• Vaccination against influenza and pneumococcus• Pulmonary rehabilitation• Oxygen therapy for hypoxemia However, the treatment landscape is evolving. Because asbestosis can behave like other progressive fibrosing interstitial lung diseases, antifibrotic therapies are increasingly considered for patients with progressive disease. Nintedanib, approved for progressive fibrosing ILD, may slow lung function decline in patients with progressive asbestosis. Early studies of pirfenidone suggest acceptable safety and potential benefit, though definitive evidence remains limited. Another critical dimension of asbestos exposure is malignancy risk. Asbestos causes two to six times more lung cancers than mesotheliomas, making asbestos-related lung cancer a major public health burden. The interaction with smoking is particularly dangerous
• A Comprehensive Clinical Guide to Glomerulonephritis for the Hospitalist 27.03.2026 35min

  In this episode of Hospital Medicine Unplugged, we sprint through glomerulonephritis—recognize the nephritic syndrome, decode complement patterns and immunofluorescence clues, and manage diseases ranging from self-limited post-infectious GN to rapidly progressive crescentic disease. We start with the clinical syndrome of glomerulonephritis, defined by glomerular inflammation producing hematuria, hypertension, edema, and reduced kidney function. The classic picture is nephritic syndrome—tea- or cola-colored urine, oliguria, periorbital edema, and elevated blood pressure. At the microscopic level, RBC casts are the pathognomonic finding, proving that bleeding originates from the glomerulus rather than the urinary tract. Understanding disease requires revisiting the glomerular filtration barrier, composed of three layers: fenestrated endothelium, the glomerular basement membrane (GBM), and podocytes connected by slit diaphragms. This barrier normally filters plasma while retaining proteins. Podocytes are terminally differentiated and poorly regenerative, making them particularly vulnerable to immune-mediated injury. The core pathophysiology of GN is immune-mediated inflammation. Antibodies, immune complexes, and complement activation trigger inflammatory cascades within the glomerulus. This leads to endocapillary proliferation, mesangial expansion, and leukocyte infiltration, narrowing capillary lumens and lowering GFR. Capillary wall damage allows red blood cells to leak into urine, while the sudden decline in filtration drives sodium and water retention, producing hypertension and edema. Modern classification emphasizes pathogenesis rather than morphology, and most GN falls into five categories: • Immune-complex GN – granular immunoglobulin deposition (post-infectious GN, IgA nephropathy, lupus nephritis, MPGN)• Pauci-immune GN – minimal immune deposition, typically ANCA-associated vasculitis• Anti-GBM disease – linear IgG staining along the basement membrane• Monoclonal immunoglobulin GN – related to plasma cell disorders• C3 glomerulopathy – dominant complement deposition from alternative pathway dysregulation Epidemiology varies by disease. Post-streptococcal GN primarily affects children aged 2–10 years, particularly in developing regions. In contrast, IgA nephropathy is the most common primary glomerular disease worldwide and typically presents in young adults. Interestingly, epidemiology has shifted: childhood PSGN is declining, while adult infection-related GN—often associated with staphylococcal infections—is increasing. Clinical presentation depends on the underlying disease. Post-streptococcal GN typically occurs 1–12 weeks after a streptococcal infection, producing abrupt edema, hypertension, and hematuria. IgA nephropathy, in contrast, often presents with synpharyngitic hematuria—visible hematuria occurring simultaneously with an upper respiratory infection. The urinalysis is the diagnostic cornerstone. Key findings include dysmorphic red blood cells, RBC casts, and mild-to-moderate proteinuria. Complement levels help narrow the differential: • Low C3 and low C4: lupus nephritis, cryoglobulinemia, immune-complex MPGN• Low C3 with normal C4: post-infectious GN or C3 glomerulopathy• Normal complement: IgA nephropathy, ANCA-associated GN, anti-GBM disease A crucial teaching point: C3 should normalize within 6–8 weeks in post-streptococcal GN. Persistent hypocomplementemia suggests another diagnosis, such as lupus nephritis or MPGN. Additional testing includes ASO titers and anti-DNase B antibodies for streptococcal infection, autoimmune markers such as ANA and ANCA, and viral testing for hepatitis B, hepatitis C, and HIV. Imaging plays a limited role. Renal ultrasound typically shows normal or enlarged kidneys in acute GN, helping distinguish acute inflammatory disease from chronic kidney disease. When the diagnosis remains unclear—or when disease is severe—a kidney biopsy is essential. Histology reveals ch
• Modern Clinical Management of Thyroid Carcinoma and the Hospitalist's Role in Coordination 25.03.2026 29min

  In this episode of Hospital Medicine Unplugged, we sprint through thyroid cancer—understand the epidemiologic paradox of rising incidence but stable mortality, stage disease using modern AJCC criteria, apply ATA recurrence risk stratification, and tailor therapy from surgery and radioiodine to targeted molecular treatments. We start with the epidemiology of thyroid carcinoma, the most common endocrine malignancy and the ninth most common cancer worldwide. In 2022 alone, there were roughly 821,000 new cases and 47,500 deaths globally. The disease shows a strong female predominance—about three quarters of cases occur in women, and the median age at diagnosis is in the early 50s. Notably, thyroid cancer is also the most common malignancy among adolescents and young adults aged 16–33 years. One of the most striking trends is the dramatic rise in incidence over the past four decades. Global age-standardized incidence increased substantially from about 2.1 per 100,000 in 1990 to over 3.1 per 100,000 in 2017, with extremely high rates reported in countries such as South Korea, Cyprus, Ecuador, China, and Turkey. Yet mortality has remained remarkably stable at roughly 0.5 per 100,000, suggesting that much of the increase reflects overdiagnosis rather than a true surge in aggressive disease. The driver behind this phenomenon is increased detection of small papillary thyroid cancers, often discovered incidentally during thyroid ultrasonography or cross-sectional imaging. Some studies estimate that more than 75% of thyroid cancers globally may represent overdiagnosis, particularly in high-income countries where imaging is widespread. Encouragingly, incidence rates have begun to plateau or decline in some regions following guideline changes discouraging unnecessary biopsy and treatment of very small nodules. Next, we turn to staging, which guides prognosis and management. The AJCC 8th edition TNM staging system introduced an important shift by raising the prognostic age cutoff from 45 to 55 years. This reflects the excellent survival outcomes seen in younger patients. For patients younger than 55 years, staging is remarkably simple:• Stage I: any tumor size, any lymph node status, no distant metastasis• Stage II: distant metastasis present This simplified system reflects the outstanding prognosis in younger individuals, with more than 98% survival regardless of tumor characteristics. For patients 55 years and older, staging becomes more detailed and incorporates tumor size, lymph node involvement, and extrathyroidal extension. Importantly, the 8th edition refined the definition of extrathyroidal extension so that only gross invasion of strap muscles qualifies for T3b staging, which has downstaged many patients and improved prognostic accuracy. However, staging alone does not fully predict recurrence. That role belongs to the American Thyroid Association (ATA) risk stratification system, which categorizes patients as low, intermediate, or high risk of recurrence. Approximate recurrence rates are:• Low risk: ~1.5%• Intermediate risk: ~5% overall• High risk: ~25% A key innovation in ATA management is dynamic risk stratification, where risk is continuously updated based on response to therapy. Response categories include:• Excellent response: ~4.7% recurrence risk• Indeterminate response: ~17% recurrence• Biochemically incomplete: ~58% recurrence• Structurally incomplete: ~84% recurrence This dynamic approach allows clinicians to de-escalate surveillance and treatment for patients who demonstrate excellent responses over time. At the molecular level, thyroid cancer has a remarkably simple genomic landscape, dominated by mutations activating the MAPK signaling pathway. The most common driver mutation is BRAF V600E, found in about 60% of papillary thyroid cancers. This mutation is associated with classic and tall-cell variants, increased lymph node metastases, and reduced responsiveness to radioactive iodine due to suppression of th
• Anaphylaxis: Mechanisms, Triggers, and Clinical Management in the Hospitalized Patient 23.03.2026 29min

  In this episode of Hospital Medicine Unplugged, we sprint through anaphylaxis—recognize the rapid systemic reaction, understand the mast-cell storm driving shock, and deliver epinephrine immediately to prevent cardiovascular collapse. We begin with the definition and diagnostic framework. Anaphylaxis is a severe, rapid-onset, life-threatening systemic hypersensitivity reaction. When it progresses to circulatory collapse with profound vasodilation and vascular leak, it becomes anaphylactic shock, a form of distributive shock with relative hypovolemia. Modern guidelines define anaphylaxis clinically: acute onset of illness with skin or mucosal symptoms plus respiratory compromise, hypotension, or severe gastrointestinal symptoms, or hypotension/bronchospasm after known allergen exposure—even without skin findings. Next comes epidemiology. Anaphylaxis occurs in roughly 50–112 episodes per 100,000 person-years, and 1.6–5.1% of adults in the United States experience an episode during their lifetime. Fortunately, modern treatment has kept mortality low. Case fatality rates among emergency presentations are about 0.25–0.33%, translating to roughly 186–225 deaths per year in the United States. Triggers vary by age. Food-induced anaphylaxis predominates in young children, while medication-induced reactions are more common in adults, especially those over age 50. At the core of anaphylaxis lies mast-cell and basophil activation. In classic IgE-mediated type I hypersensitivity, an allergen first sensitizes the immune system, leading B cells to produce IgE antibodies that bind to high-affinity FcεRI receptors on mast cells and basophils. On re-exposure, allergen cross-linking of IgE triggers rapid cellular degranulation. This releases a cascade of mediators including: • Histamine and tryptase• Leukotrienes and prostaglandins• Platelet-activating factor (PAF)• Cytokines such as IL-4 and IL-6 These mediators cause vasodilation, endothelial barrier disruption, bronchoconstriction, and massive capillary leak, shifting fluid from the intravascular space to tissues. The result is hypotension, airway compromise, and multisystem dysfunction. Not all anaphylaxis is IgE mediated. Alternative mechanisms include IgG-mediated reactions, complement activation, contact system activation, and direct mast-cell activation via MRGPRX2 receptors. Clinically, these non-IgE pathways can produce identical presentations, which is why anaphylaxis remains a clinical diagnosis rather than a laboratory one. The most common triggers fall into three major groups: • Foods (≈32–37%)• Medications (≈21–58%)• Insect venom (≈15–25%) In the United States, nine foods account for over 90% of IgE-mediated food allergies: milk, egg, wheat, soy, peanuts, tree nuts, fish, shellfish, and sesame. Peanuts remain the leading cause of fatal food-related anaphylaxis. An emerging cause is alpha-gal syndrome, a delayed meat allergy triggered by tick bites, affecting tens to hundreds of thousands of individuals in the United States. Medications are the most common trigger in adults, particularly beta-lactam antibiotics, followed by NSAIDs, biologic agents, chemotherapy drugs, and ACE inhibitors. Another important concept is cofactors—conditions that lower the threshold for anaphylaxis. These include exercise, alcohol, infection, menstruation, and NSAID use. A classic example is food-dependent exercise-induced anaphylaxis, where patients tolerate a food normally but develop anaphylaxis if they exercise soon after ingestion. Diagnosis relies on clinical criteria, most commonly the NIAID/FAAN criteria. Anaphylaxis is highly likely when there is acute involvement of skin or mucosa plus respiratory compromise or hypotension, multisystem involvement after allergen exposure, or isolated hypotension after exposure to a known trigger. Laboratory confirmation is not required in the acute setting, but serum tryptase measured 90 minutes to 4 hours after symptom onset can support the diagno
• Upper Motor Neuron Syndrome: Pathophysiology and Clinical Management in the Hospitalized Patient 20.03.2026 27min

  In this episode of Hospital Medicine Unplugged, we sprint through upper motor neuron (UMN) syndromes—how spasticity develops, how to separate true reflex hyperexcitability from fixed stiffness, and how to diagnose and manage major UMN diseases like PLS and hereditary spastic paraplegia. We begin with spasticity, a defining feature of UMN injury that is not simply an immediate “release phenomenon.” Its delayed appearance after stroke or spinal cord injury points to maladaptive plasticity in both the spinal cord and brain. The core problem is loss of descending inhibitory control, with reduced corticospinal input, increased reticulospinal drive, impaired spinal inhibitory circuits, heightened alpha motor neuron excitability, and reduced postactivation depression, especially with immobilization. Clinically, spasticity is a velocity-dependent increase in tone caused by hyperexcitable stretch reflexes. But bedside hypertonia often has two components: reflex-mediated spasticity and intrinsic soft tissue stiffness from contracture and rheologic muscle change. That distinction matters. The Modified Ashworth Scale measures overall resistance, but the Tardieu Scale better separates dynamic spasticity from fixed mechanical tightness. We then turn to primary lateral sclerosis (PLS), the prototypical adult UMN-predominant degenerative disorder. The 2020 consensus criteria define probable PLS as 2–4 years of progressive UMN syndrome and definite PLS as more than 4 years of symptoms. That time threshold matters because shorter duration carries higher risk of later ALS conversion. Even in clinically pure PLS, minor EMG abnormalities like fasciculations or fibrillations can occur, especially with longer disease duration. Next is hereditary spastic paraplegia (HSP), a genetically diverse disorder marked by bilateral leg spasticity, hyperreflexia, and extensor plantar responses from length-dependent corticospinal tract degeneration. HSP is classified into pure forms, where spastic paraparesis dominates, and complex forms, where additional neurologic features appear. Although SPAST (SPG4) and SPG7 are among the most common mutations, a genetic diagnosis is still achieved in only a minority of patients. MRI is the gold standard imaging study in suspected UMN disease. Key findings include corticospinal tract T2/FLAIR hyperintensity, especially in the posterior limb of the internal capsule and cerebral peduncles, as well as the “motor band sign,” a T2/SWI hypointensity in the precentral gyrus reflecting iron deposition. Motor cortex atrophy may be even more sensitive than the physical exam for detecting UMN degeneration and can appear before overt clinical signs. We also highlight the distinction between pseudobulbar palsy and bulbar palsy. Pseudobulbar palsy comes from bilateral corticobulbar UMN lesions and produces spastic dysarthria, brisk jaw jerk, and exaggerated gag reflex. It is often accompanied by pseudobulbar affect—uncontrollable laughing or crying out of proportion to context. In contrast, bulbar palsy reflects LMN dysfunction of cranial nerve nuclei or nerves. Management of spasticity follows a stepwise approach. Start with physical therapy, stretching, splinting, bracing, and positioning. For focal spasticity, botulinum toxin A has the strongest evidence and is preferred because it improves tone without systemic sedation. For generalized spasticity, oral agents include baclofen, tizanidine, benzodiazepines, and dantrolene, though benefit is often limited by sedation or weakness. In severe refractory cases, intrathecal baclofen pumps provide greater efficacy at lower doses—but pump failure can cause life-threatening withdrawal. We close with the take-home moves: recognize that spasticity is dynamic neurophysiology plus biomechanics, use MRI and timeline to refine the diagnosis, distinguish pseudobulbar from bulbar syndromes, and treat spasticity with a layered rehab-first strategy before escalating to botulinum toxin or int
• Endovascular Infections: Vascular Grafts, CIEDs, Mycotic Aneurysms & Lemierre Syndrome 18.03.2026 1u 2min

  In this episode of Hospital Medicine Unplugged, we break down endovascular infections—vascular graft infections, mycotic aneurysms, CIED infections, and septic thrombophlebitis syndromes—focusing on modern epidemiology, evolving microbiology, advanced imaging, and high-yield management strategies. We begin with epidemiology clinicians should know. Vascular graft infections occur in ~0.5–6% of vascular reconstructions, while endovascular device infections occur in ~0.2–5% of procedures, with TEVAR carrying higher infection risk than abdominal repairs. Meanwhile, cardiac implantable electronic device (CIED) infections have increased substantially, reflecting growing device use. Next we review key microbiology. Gram-positive cocci cause most vascular graft infections, with coagulase-negative staphylococci now more common than S. aureus. MRSA is increasingly prevalent and linked to worse outcomes, while Pseudomonas aeruginosa leads among gram-negative pathogens. For mycotic aneurysms, Salmonella species remain classic causes, with rare pathogens including Listeria and Mycobacterium tuberculosis. We then highlight important clinical syndromes.Lemierre syndrome presents with pharyngitis, internal jugular vein thrombosis, and septic emboli (often pulmonary) and is classically caused by Fusobacterium necrophorum, though MRSA and polymicrobial infections are increasingly recognized. Pylephlebitis, sometimes called the abdominal variant of Lemierre syndrome, involves septic thrombosis of the portal venous system. Diagnosis relies heavily on advanced imaging. CTA is typically the first-line test, while 18F-FDG PET/CT provides high sensitivity (~94%) and excellent negative predictive value, especially in late graft infections. TEE remains essential for suspected CIED infection, though repeat imaging may be needed if initial studies are negative. Management requires combined antimicrobial and procedural strategies.• ≥6 weeks of antibiotics for most vascular graft infections• Device removal for confirmed CIED infection, with early extraction improving survival• 3–6 weeks of antibiotics for Lemierre syndrome, often metronidazole plus a β-lactam, with MRSA coverage in high-risk patients• Lifelong suppressive therapy may be needed when infected devices cannot be removed We close with key controversies and outcomes. Anticoagulation for septic thrombophlebitis remains debated, though many experts consider 6–12 weeks of therapy in selected patients. Despite advances, vascular graft infections and mycotic aneurysms carry high mortality—often exceeding 30% at one year—especially with MRSA. Early recognition, PET/CT-guided diagnosis, aggressive antibiotics, and timely device removal remain the pillars of care for these complex infections.